Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
A Post-marketing Real-world Study for Evaluating Effectiveness and Safety of Spartina® (Tirzepatide Manufactured by CinnaGen) in Patients With Obesity and Overweight
Cinnagen
175 participants
Nov 11, 2025
OBSERVATIONAL
Summary
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1. Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight? 2. Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight? In this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)
Eligibility
Inclusion Criteria3
- Male or female ≥18 years of age
- Willingness for signing and having signed the informed consent form
- BMI ≥30 kg/m² or ≥27 kg/m² with ≥1 weight-related comorbidity
Exclusion Criteria5
- Prior use of any GLP-1 agonist in the last 6 months
- Type 1 diabetes mellitus
- Any condition or circumstance that might pose a risk to the subject or interfere with the ability to acquire satisfactory clinical data
- Pregnancy or breast-feeding
- Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07262762